Golden
Immatics Biotechnologies

Immatics Biotechnologies

A biopharmaceutical company focused on the discovery and development of immunotherapy of cancer

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

October 2017

Immatics Biotechnologies raises a $58,000,000 series E round from dievini Hopp Biotech Holding, Amgen, AT Impf and Wellington Partners.

January 9, 2017

Immatics Biotechnologies raises a $30,000,000 series E round from Amgen Ventures and Grazia Equity.

October 15, 2013

Immatics Biotechnologies raises a $43,744,400 series D round from Wellington Partners.

September 21, 2010

Immatics Biotechnologies raises a $70,848,000 series C round from Wellington Partners.

April 15, 2005

Immatics Biotechnologies raises a $7,500,000 series B round from Grazia Equity and Wellington Partners.

People

Name
Role
LinkedIn

Benedikt Kronberger

Investor

Jochen Andritzky

Investor

Philipp Belter

Investor

Rainer Strohmenger

Investor

Ralf Knobel

Investor

Tetyana Astashkina

Investor

Further reading

Title
Author
Link
Type
Date

Immatics Initiates Second Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers

Immatics

Web

Documentaries, videos and podcasts

Title
Date
Link
+ Add new row

Companies

Company
CEO
Location
Products/Services
+ Add new row